To salt or not to salt in kidney diseases? Not more than quantum satis!
Authors:
K. Matoušovic 1; Ľ. Podracká 2
Authors‘ workplace:
Interní klinika 2. lékařské fakulty UK a FN Motol Praha, přednosta prof. MUDr. Milan Kvapil, CSc., MBA
1; I. klinika detí a dorastu UPJŠ LF a DFN Košice, Slovenská republika, prednostka prof. MUDr. Ľudmila Podracká, CSc.
2
Published in:
Vnitř Lék 2012; 58(7 a 8): 66-70
Category:
80th Birthday MUDr. Miroslav Mydlík, DrSc.
Overview
The salt intake in former Czechoslovakia is twice as high as recommended 5 g/24 hours, which corresponds to 85 mmol//24 hours of sodium in the urine. In the population, the systemic blood pressure level correlates with a urinary excretion of sodium/24 hours. On the other hand, limited salt intake decreases blood pressure in salt-sensitive hypertensive patients. Albuminuria also positively correlates with a salt intake in the population. In patients with renal disease, a diet with low salt content suppresses proteinuria, and, in contrast, proteinuria is elevated with increased salt intake. The positive influence of the decreased salt intake on the progression of renal insufficiency was confirmed in many experimental studies. However, in humans, this finding was not unequivocally established in control randomized studies. The high salt intake worsens metabolic acidosis in patients with renal insufficiency. Salt is detrimental to the kidneys either by increased systemic and intraglomerular blood pressures or by pressure independent mechanisms of the tissue injury, which are mediated by a higher sodium concentration. The present knowledge concerning the relationship between sodium intake and extracellular fluid volume probably will be modified in light of new discoveries about the osmotically inactive sodium. The public enlightenment and medical application of these new findings related to harmful effects on an inappropriate salt intake in treatment of the kidney disease and in other fields of medicine is strongly desirable.
Key words:
salt – sodium – nephropathy – progression – acid base balance
Sources
1. Brown IJ, Tzoulaki I, Candeias V et al. Salt intakes around the world: implications for public health. Int J Epidemiol 2009; 38: 791–813.
2. WHO/FAO. Diet, nutrition and the prevention of chronic diseases. World Health Organ Tech Rep Ser 2003; 916: i–viii, 1–149.
3. Guyton AC. Abnormal renal function and autoregulation in essential hypertension. Hypertension 1991; 18 (5 Suppl): III49–III53.
4. Heer M, Baisch F, Kropp J et al. High dietary sodium chloride consumption may not induce body fluid retention in humans. Am J Physiol Renal Physiol 2000; 278: F585–F595.
5. Titze J, Shakibaei M, Schaffhuber et al. Glycosaminoglycan polymerization may enable osmoticaly inactive Na+ storage in the skin. Am J Pysiol Heart Circ Physiol 2004; 287: H203–H208.
6. Titze J, Ritz E. Salt and its effect on blood pressure and target organ damage: new pieces in an old puzzle. J Nephrol 2009; 22: 177–189.
7. Rabelink TJ, Rotmans JI. Salt is getting under our skin. Nephrol Dial Transplant 2009; 24: 3282–3283.
8. Schafflhuber M, Volpi N, Dahlmann A et al. Mobilization of osmotically inactive Na+ by growth and by dietary salt restriction in rats. Am J Physiol Renal Physiol 2007; 292: F1490–F1500.
9. Espinel CH. The influence of salt intake on the metabolic acidosis of chronic renal failure. J Clin Invest 1975; 56: 286–291.
10. Kraut JA, Madias NE. Consequences and therapy of the metabolic acidosis of chronic kidney disease. Pediatr Nephrol 2011; 26: 19–28.
11. Stamler J, Rose G, Elliott P et al. Findings of the International Cooperative INTERSALT Study. Hypertension 1991; 17 (Suppl 1): I9–I15.
12. Matyas E, Jeitler K, Horvath K et al. Benefit assessment of salt reduction in patients with hypertension: systematic overview. J Hypertens 2011; 29: 821–828.
13. Ritz E. Salt and hypertension. Nephrology (Carlton) 2010; 15 (Suppl 2): 49–52.
14. Ying WZ, Aaron K, Wang PX et al. Potassium inhibits dietary salt-induced transforming growth factor-beta production. Hypertension 2009; 54: 1159–1163.
15. Geleijnse JM, Hofman A, Witteman JC et al. Long-term effects of neonatal sodium restriction on blood pressure. Hypertension 1997; 29: 913–917.
16. Cooper R, Liu K. Correlation between salt intake, blood pressure and family history of hypertension. Am J Clin Nutr 1980; 33: 2218–2220.
17. Simmons-Morton DG, Obarzanek E. Diet and blood pressure in children and adolescent. Pediatr Nephrol 1997; 11: 244–249.
18. Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann NY Acad Sci 2002; 970: 89–100.
19. Joffe HV, Adler GK. Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation. Heart Fail Rev 2005; 10: 31–37.
20. Vegter S, Perna A, Postma MJ et al. Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol 2012; 23: 165–173.
21. Boero R, Pignataro A, Quarello F. Salt intake and kidney disease. J Nephrol 2002; 15: 225–229.
22. Krikken JA, Laverman GD, Navis G. Benefits of dietary sodium restriction in the management of chronic kidney disease. Curr Opin Nephrol Hypertens 2009; 18: 531–538.
23. Antonios TF, MacGregor GA. Salt – more adverse effects. Lancet 1996; 348: 250–251.
24. Sanders PW. Vascular consequences of dietary salt intake. Am J Physiol Renal Physiol 2009; 297: F237–F243.
25. Puschett JB, Agunanne E, Uddin MN. Emerging role of the bufadienolides in cardiovascular and kidney diseases. Am J Kidney Dis 2010; 56: 359–370.
26. Shaldon S, Vienken J. Salt, the neglected silent killer. Semin Dial 2009; 22: 264–266.
27. Bakris GL, Weir MR. Salt intake and reductions in arterial pressure and proteinuria. Is there a direct link? Am J Hypertens 1996; 9: 200S–206S.
28. Cianciaruso B, Bellizzi V, Minutolo R et al. Salt intake and renal outcome in patients with progressive renal disease. Miner Electrolyte Metab 1998; 24: 296–301.
29. Kuriyama S, Tomonari H, Ohtsuaka H et al. Salt intake and the progression of chronic renal diseases. Nippon Jinzo Gakkai Shi 2003; 45: 751–758.
30. Jones-Burton C, Mishra SI, Fink JC et al. An in-depth review of the evidence linking dietary salt intake and progression of chronic kidney disease. Am J Nephrol 2006; 26: 268–275.
31. Ritz E, Dikow R, Morath C et al. Salt – a potential “uremic toxin”? Blood Purif 2006; 24: 63–66.
32. Amaha M, Ohashi Y, Sakai K et al. Salt intake and the progression of renal failure in patients with chronic kidney disease. Nihon Jinzo Gakkai Shi 2010; 52: 952–958.
33. Weir MR, Dengel DR, Behrens MT et al. Salt-induced increases in systolic blood pressure affect renal hemodynamics and proteinuria. Hypertension 1995; 25: 1339–1344.
34. Suckling RJ, He FJ, MacGregor GA. Altered dietary salt intake for preventing and treating diabetic kidney disease. Cochran Database Syst Review 2010; 8: CD006763.
35. Imanishi M, Yoshioka K, Okumura M et al. Sodium sensitivity related to albuminuria appearing before hypertension in type 2 diabetic patients. Diabetes Care 2001; 24: 111–116.
36. Verhave JC, Hillege HL, Burgerhof JG et al. PREVEND Study Group Sodium intake affects urinary albumin excretion especially in overweight subjects. J Intern Med 2004; 256: 324–330.
37. Verhave JC, Gansevoort RT, Hillege HL et al. PREVEND Study Group. An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kidney Int Suppl 2004; 92: S18–S21.
38. Dickinson BD, Havas S. Council on Science and Public Health, American Medical Association. Reducing the population burden of cardiovascular disease by reducing sodium intake – a report of the Council on Science and Public Health. Arch Intern Med 2007; 167: 1460–1468.
39. Ritz E, Koleganova N, Piecha G. Role of sodium intake in the progression of chronic kidney disease. J Ren Nutr 2009; 19: 61–62.
40. Ritz E, Mehls O. Salt restriction in kidney disease – a missed therapeutic opportunity? Pediatr Nephrol 2009; 24: 9–17.
41. Sanders PW. Salt intake, endothelial cell signaling, and progression of kidney disease. Hypertension 2004; 43: 142–146.
42. Sanders PW. Effect of salt intake on progression of chronic kidney disease. Curr Opin Nephrol Hypertens 2006; 15: 54–60.
43. Matoušovic K, Štekláčová A, Bohdanecká M et al. I mírně snížený obsah soli v dietě zpomalí progresi ledvinové nedostatečnosti u potkanů po 5/6 nefrektomii. Lék Obzor 2010; 59: 512–513.
44. Charra B, Chazot C. The neglect of sodium restriction in dialysis patients: a short review. Hemodial Int 2003; 7: 342–347.
45. Szczech LA, Reddan DN, Klassen PS et al. Interactions between dialysis-related volume exposures, nutritional surrogates and mortality among ESRD patients. Nephrol Dial Transplant 2003; 18: 1585–1591.
46. Shaldon S, Vienken J. Beyond the current paradigm: recent advances in the understanding of sodium handling. An introduction. Semin Dial 2009; 22: 252.
47. Twardovski ZJ. Sodium, hypertension, and an explanation of the “lag phenomenon” in hemodialysis patients. Hemodial Int 2008; 12: 412–425.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2012 Issue 7 a 8
Most read in this issue
- Myocardial infarction the young – our results and experience
- An anaesthesiologist’s perspective on requirements for pre-surgery examinations
- Megakaryopoesis and platelet genesis
- Aldosterone antagonists in chronic heart failure treatment